Treatment with plant-derived salvianolic acid B (SAB) reduced skin fibrosis in a mouse model of scleroderma. The findings suggest…
Articles by José Lopes, PhD
A Phase 2a clinical trial will test the investigational therapy GLPG1690 in patients with diffuse cutaneous scleroderma. The double-blind,…
Inhibiting a key innate immunity protein known as TLR4 with a compound called TAK242 prevented and reversed skin and lung…
Mutations in the FAM111B gene are rare in scleroderma patients and not associated with disease development, according to…
Patients with scleroderma and pulmonary arterial hypertension (PAH) have increased levels of two serum proteins, midkine (MDK) and…
Patients with both scleroderma and systemic lupus erythematosus (SLE) are younger at diagnosis, are more often women, and have…
A protein involved in inflammation and tissue regrowth — HMGB1 — may be the main driver of blood vessel damage…
A key innate immunity protein called TLR4 is a key driver of organ fibrosis, according to a new study…
Treatment with Opsumit (macitentan) and Esbriet (pirfenidone) provided stable improvements in a scleroderma patient with interstitial…
The occurrence of blood clots in the veins of scleroderma patients is rare and does not change patients’ survival rates,…